** Shares of genetics-testing firm Tempus AI TEM.O up 10.4% at $73.19 premarket

** Reports record total contract value of over $1.1 bln and net revenue retention of ~126%

** Says it signed data agreements with more than 70 customers in 2025, including AstraZeneca AZN.L, Pfizer PFE.N, Merck MRK.N and other major drugmakers

** Co says engagement with life sciences firms at "record levels," giving visibility to continued growth in 2026 and beyond

** Preliminary 2025 data & applications revenue estimated at $316 mln, up ~31% YoY

** Says FY prelim 2025 revenue about $1.27 billion, up roughly 83%

** TEM stock gained ~76% over the past year

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))